Targeted delivery of paclitaxel and doxorubicin to cancer xenografts via the nanoparticle of nano-diamino-tetrac

Thangirala Sudha, Dhruba J. Bharali, Murat Yalcin, Noureldien H E Darwish, Melis Debreli Coskun, Kelly A. Keating, Hung Yun Lin, Paul J. Davis, Shaker A. Mousa

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The tetraiodothyroacetic acid (tetrac) component of nano-diamino-tetrac (NDAT) is chemically bonded via a linker to a poly(lactic-co-glycolic acid) nanoparticle that can encapsulate anticancer drugs. Tetrac targets the plasma membrane of cancer cells at a receptor on the extracellular domain of integrin αvβ3. In this study, we evaluate the efficiency of NDAT delivery of paclitaxel and doxorubicin to, respectively, pancreatic and breast cancer orthotopic nude mouse xenografts. Intra-tumoral drug concentrations were 5-fold (paclitaxel; P<0.001) and 2.3-fold (doxorubicin; P<0.01) higher than with conventional systemic drug administration. Tumor volume reductions reflected enhanced xenograft drug uptake. Cell viability was estimated by bioluminescent signaling in pancreatic tumors and confirmed an increased paclitaxel effect with drug delivery by NDAT. NDAT delivery of chemotherapy increases drug delivery to cancers and increases drug efficacy.

Original languageEnglish
Pages (from-to)1305-1315
Number of pages11
JournalInternational Journal of Nanomedicine
Volume12
DOIs
Publication statusPublished - Feb 15 2017

Keywords

  • Doxorubicin
  • Integrin
  • Nanoparticle
  • Nanotetrac
  • NDAT
  • Paclitaxel
  • Tetraiodothyroacetic acid
  • Xenografts

ASJC Scopus subject areas

  • Bioengineering
  • Biophysics
  • Biomaterials
  • Drug Discovery
  • Organic Chemistry

Fingerprint Dive into the research topics of 'Targeted delivery of paclitaxel and doxorubicin to cancer xenografts via the nanoparticle of nano-diamino-tetrac'. Together they form a unique fingerprint.

Cite this